ARS Pharmaceuticals Misses July Formulary Deadline but Cuts Costs
Event summary
- No new commercial formulary additions for neffy in the July 1, 2026 cycle despite ongoing payer discussions.
- 2026 cash-based operating expenses lowered to $248 million due to second-half spending reductions.
- Phase 2b chronic spontaneous urticaria (CSU) program interim data readout expected Q4 2026.
- Company reaffirms neffy base business supports a path to cash-flow breakeven in 2027.
The big picture
ARS Pharmaceuticals' inability to secure new formulary additions for neffy highlights the challenges of payer negotiations in the biopharmaceutical industry. The company's cost-cutting measures and focus on cash-flow breakeven by 2027 reflect broader trends of financial discipline amid regulatory and market pressures. The potential expansion into chronic spontaneous urticaria (CSU) represents a strategic pivot to diversify revenue streams beyond allergic reactions.
What we're watching
- Payer Negotiations
- Whether ARS Pharmaceuticals can secure future formulary additions for neffy despite missing the July 1, 2026 cycle.
- Cost Discipline
- The pace at which ARS Pharmaceuticals can sustain reduced operating expenses while maintaining growth in the neffy base business.
- Clinical Pipeline
- How interim data from the Phase 2b CSU program in Q4 2026 could impact the company's long-term growth prospects.
Related topics